Molomics

Molomics advances the search for structurally novel small-molecule therapeutics by combining artificial intelligence (AI) with human collective intelligence (HCI). With molecules being co-designed in silico between machines and humans, we anticipate our drug candidates to be more effective and safer, thereby increasing clinical development success rates. Molomics’ primary focus is on Parkinson's disease (PD). Current programs address L-DOPA-induced dyskinesia (LID) through strategies involving GPCRs (G-protein-coupled receptors), such as allosteric modulation, applied in drug discovery and development.Our drug discovery program progresses through three phases: feasibility studies, drug design phase, and partial preclinical analysis. Collaborating with research institutions and industry partners in biotechnology and pharmaceuticals to unlock new opportunities and ensure the design of efficient and safer drugs.